Clinical Significance: To reduce the significant complications in irradiated patients, the clinical implication of these radioprotective agents have emerged as potential drugs and with anti-tumour effect in the radiotherapy of various cancers including oral carcinomas.
INTRODUCTION
Radioprotective agents have been used to prevent damage to the tissues from the radiations that have been produced while diagnostic and treatment phases of carcinomas. As, oral cancer is one of the most prevalent cancers and is one of the 10 most common causes of mortality, it accounts for about 2% in male and 1% in female death due to oral cancer. 1 Over 40% of cancer patients will require radiotherapy during their management, at some time or other, either for curative or palliative purpose. 2 The type of radiations used in cancer treatment are called ionizing radiation. These ionizing radiation produces free radicals in cell by a process of radiolysis of water. As these free radicals interact with cellular macro and micro-molecules which leads to cell dysfunction and mortality in tumour cells as well as normal cells. 3 The tumor cells proliferate very rapidly, and cause, a central necrotic and hypoxic region which is a radioresistant area. To overcome this problem, higher doses of radiation must be delivered to control the tumor, which inturn leads to more toxic effect on surrounding well perfused vascularised normal tissues. This necessitates the protection of normal cells surrounding the tumor from radiation injury. 4 Various efforts to reduce the toxicity from radiation injuries have been made both by non-pharmacological intervention or technological improvement in radiation delivery system and by pharmacological modifiers, called as radioprotective agents.
In 1942, Dale introduced the terms radioprotection and radioprotective agents and also carried out many studies using enzymes as indicative molecules. However, in 1949, Patt and his co-workers were the first to investigate the radioprotective effect of amino-acid cysteine when exposed to lethal doses of X-rays. 5 The most significant contribution of the Walter Reed Army Institute of Research (WRAIR) initiatives the development of WR-2721, S-2-(3-aminopropylamino) ethylphosphorothioic acid, and many related phosphorothioates, which were first synthesized by Akerfeldt in 1959 as radioprotective agents.
ABSTRACT
In the field of medicine or dentistry, cancer is one of the most common causes for death of the individual worldwide, in which oral cancer accounts for about 10% of it. One of the most important treatment modalities for cancer includes radiotherapy. During radiotherapy, exposure of the normal tissue to these ionizing radiations, results in mutagenesis and cell death. Several modalities and clinical approaches have been made to reduce these early and late complications of the radiotherapies and one among them is, by the means of pharmacological agents. Many experimental and clinical studies have given rise to new concepts of chemical and molecular pharmacological agents that could be effective in protection and treatment of radiation damage to surrounding normal tissues.
RADIATION INJURY AND TISSUE DAMAGE
Ionizing radiation which causes genetic mutation or cell death can be divided into photon radiation (X-rays and Gamma rays) and particulate radiation (electrons, protons, neutrons, alpha (α) and beta (β) particles). Some types of ionizing radiation have more energy (high-energy photons are emitted from radioactive substances such as cobalt, cesium, iridium) than other (electron beam produced by linear accelerator) and henceforth have more penetrating power into the tissue. Radiation oncologists select the type and energy of radiation that is most suitable for the particular cancer patient. 3 Ionizing radiation exerts its effect through the production of free radicals that destroys DNA and structures such as cell membrane of the target cell. 4, 5 Following whole body exposure to moderate doses (2-5Gy), damage to the hematopoietic cells is the major cause of morbidity, while at higher doses (5-10Gy), damage to the gastrointestinal tract, lung and brain also contributes to the total effect. 6, 7 Although in these cases death is rare, but late effects of radiation sequel may severely compromise the quality of life of cancer survivors. 4 Complications of head and neck radiotherapy include oral mucositis, taste alterations which generally subside within several weeks after completion of treatment, but some late effects like damage to salivary glands with resultant xerostomia (irradiation exceed more than 35Gy), damage to the dentition, muscular fibrosis, osteoradionecrosis, cartilage necrosis, dysphagia and damage to the eye, ear and central nervous system are also seen. 3, 8 Effects of radiation at the molecular level of cell can be classified as given by M I Koukourakis et al. 4  Type I early radiation effects/ cellular depletion  Type II early radiation effects/ reactive gene activation  Type III late radiation effects/ tissue disorganisation  Type IV radiation effects/ stochastic effects  Type V radiation effects/ bystander effects.
To overcome these complications, some efforts have been made which includes:
Technical or non-pharmacological improvement by means of  External beam radiotherapy (Intensity modulated radiation therapy -IMRT, image guided radiotherapy -IGRT)  Stereotactic radio-surgeries.  Radioisotope bound to monoclonal antibody for tumor targeted radiotherapy (Radioimmunotherapy).
Pharmacological intervention by use of radiation modifiers/protectors
An ideal radioprotector should have the following criteria and abilities functionally: 9, 10  Free radical scavenging.  Radio oxidative damage.  Selective in protecting normal tissues from radiotherapy without protecting tumor tissue.  Absence of cumulative effect in repeated administration.  Should have an efficacy for different types of radiation (X-rays, gamma, neutrons).  Immunomodulation action.  Facilitate repair of damaged and affected organs.
CLASSIFICATION OF RADIOPROTECTIVE AGENTS
Radioprotective agents may be classified as follows:
 Based on time of radiation 11, 12  Chemical protectors or Prophylactic agents  Mitigators  Treatment or Therapeutic agents  According to their mechanism of action (MOA) ( Table-1) 
13-16
 According to their mechanistic biological activity (Table-2) 17-19
MECHANISM OF RADIATION PROTECTION

20-24
Different theories that have been propounded that include:
 Release of endogenous radioprotectors like glutathione, superoxide dismutase.  By inducing hypoxia in the tissues.  DNA repair and recovery process.
It is also well known that radioprotective activity is accomplished through different mechanisms on three special levels of cell organization, i.e. at molecular level, physiological-biochemical level and at organic level. 25 The mechanism of free radical scavenger suggests that certain agents are oxidized by free radicals, therefore forming stable compounds and incapable of reacting with other cellular components. This mechanism prevents the free radicals from reacting with the cell vital components. 
Compounds
Mechanism of action Examples
Sulfhydryl compounds
Free-radical scavenging, donation of H atom.
Cysteine, Cysteamine, Glutathione,amino-ethyl sothiourea (AET), Amifostine (WR 2127) and other WR-compounds.
Antioxidants
Free-radical scavenging.
Tempace, Vitamin A, E, & C, Tocopherol-monoglucoside (TMG), Melatonin, etc.
ACE inhibitors (Angiotensin Converting Enzymes)
Protease inhibition (through reninangiotensin system), anti-oxidation, collagen synthesis inhibition, anti-fibrotic and anti-inflammatory action.
Captopril, Enalapril, Pencillamine, Pentoxyfylline, L-158, 809, etc
Metalloelements
Metallothionine induction
Manganese chloride, Cadmium salts, Bismuth Subnitrate, etc.
Immunomodulators
Immune stimulation, increased production of cytokines Gamma-interferon, Polysaccharides AM5, AM218, Broncho-Vaxom, Trehalose dicorynomycolate, Ammonium trichloro-telluride (AS101).
Plant extracts and isolated compounds
Free-radical scavenging, antioxidation,anti-inflammatory action. Curcmin, Orientin, Vicinin, Mint
DNA binding ligands Electron transfer, free-radical scavenging Hoechst 33342
Other Compounds Free-radical-scavenging Antioxidant, Antiinflammatory action.
Melatonin, Carnosin, Tempace, Tempol, Honey bee venom Another mechanism which has been demonstrated with polymers is the repair by hydrogen donation. If a R-H molecule is converted into a R (radical R) by exposure to radiation, a protective agent can donate a hydrogen atom to this radical, restoring it to its original state.
The formation of mixed disulfides is a mechanism proposed for aminothiols and involves radioprotector binding to cellular components. Sulfhydryl compounds of the aminothiols form mixed disulfides with sulfhydryl compounds of cellular proteins. When one of these disulfides is attacked by free radicals, one of the sulfur atoms is reduced and the other is oxidized. If the sulfur atom of the protein is reduced and the sulfur atom of the protective agent is oxidized, the protein is not damaged. Binding of aminothiols and disulfides to DNA has been considered a potentially important factor in radioprotection.
In view of these considerations, Brown 22 proposed that the sulfhydryl compounds of the radioprotective aminothiols act by binding to DNA, and thereby, reversibly inhibit replication and stabilize their structure, which provides additional time for repair. Oxidation of the thiols consumes enough oxygen to reduce its tension, and it has already been demonstrated that hypoxia is radioprotective.
Also another mechanism behind this sulfyhydryl compounds of amiothiols in protecting normal tissues but not tumour cell is poor drug penetration due to poor blood perfusion in tumour cells and also presence of higher pH and alkaline phosphatase enzyme in normal tissue but not in tumour tissues (Figure 1 ). 26 Biological activity of cytokines like interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-α), granulocyte colonystimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) act as radioprotective agents by stimulating the stem cells and hematopoiesis.
Immunomodulators are another class of radioprotectors that can enhance the proportion of hematopoietic stem cells into more radio-resistant phase of the cell cycle or increase of the size of the post-irradiation stem cell population. 27, 28 Various studies and clinical trials have been done regarding the protective efficacy of various compounds like L-Carnitine which prevents the formation of free radicals by xanthine-xanthine oxidase system, 29 Palifermin-recombinant human keratinocyte growth factors, 30 herbal products like black seed (Nigella Sativa oil), 31 multiple ex-vivo studies conclude that the suppression of bone marrow hematopoietic activity post radiation therapy is mitigated significantly with ON0121.Na, 32 wheat germ-oil etc., 33 but Amifostine (WR1065) remains one of the most promising drug in clinical use presently because of its dual action nature as a free radical scavenger and in repair reaction of DNA damage 26 and is safe and practical to administer in a clinical setting. With the use of radioprotective agents in cancer therapy, normal tissues are protected but not the cancer tissues because of some specific transport process.
TRANSPORT
For example, Amifostine (WR-2721) and its derivatives are phosphoaminothionate and these pro-drugs are dephosphorylated by alkaline phosphatase enzyme. Dephosphorylated metabolites diffuse passively through the cell membrane and are oxidized in the cell. These compounds reveal chemical similarity to some other compounds in the cell and henceforth are also transported by the some special transporter leading to cellular accumulation of amifostine derivatives. 35 Different transport systems are necessary for the tissue distribution of these radioprotectors.
CONCLUSION
Radiation therapy is frequently used in the definitive management and palliative care for cancer patients. Treatment of tumor tissue inevitably results in the irradiation of surrounding normal tissues. Technological advances may result in lowering the normal tissue exposure, but it is expected that technologic approach will not completely prevent toxicity in irradiated fields. By the use of these chemical modifier or pharmacological agent, toxic effect on normal tissues can be spared in patients treated with radiotherapy or during irradiation which will improve the quality of life. In spite of discovery and clinical trials of various compounds, Amifostine, remains the promising drug currently in clinical use as a radioprotector.
